Abstract
Ischemic stroke is a leading cause of mortality and morbidity worldwide. Numerous therapeutic studies, including stem cell therapy, have been explored in order to find the possible approach treating cerebral ischemia effectively. However, massive grafted-cell death and low survival rate made us pessimistic about the widespread application of stem cell therapy. The approach of preconditioning stem cells became an attractive option due to its high cell viability after transplantation. In this review, we focused on preconditioning stem cells via cytokines, chemical drugs and other factors including interleukin 6 (IL-6), lipopolysaccharide (LPS), minocycline, melatonin and hypoxia to increase grafted stem cell survival, proliferation, migration to ischemic peri-focal area and ultimately improve neurobehavioral outcomes. We explored the underlying therapeutic efficacy of preconditioning stem cells as well as possible mechanisms and potential risks. Finally, we discussed the prospects of the application of cell-based therapy in clinical patients with ischemic stroke.
Keywords: Angiogenesis, ischemia, neuroprotection, precondition, stem cell.
Current Drug Targets
Title:Preconditioned Stem Cells: A Promising Strategy for Cell-Based Ischemic Stroke Therapy
Volume: 15 Issue: 8
Author(s): Hongxia Cai, Zhijun Zhang and Guo-Yuan Yang
Affiliation:
Keywords: Angiogenesis, ischemia, neuroprotection, precondition, stem cell.
Abstract: Ischemic stroke is a leading cause of mortality and morbidity worldwide. Numerous therapeutic studies, including stem cell therapy, have been explored in order to find the possible approach treating cerebral ischemia effectively. However, massive grafted-cell death and low survival rate made us pessimistic about the widespread application of stem cell therapy. The approach of preconditioning stem cells became an attractive option due to its high cell viability after transplantation. In this review, we focused on preconditioning stem cells via cytokines, chemical drugs and other factors including interleukin 6 (IL-6), lipopolysaccharide (LPS), minocycline, melatonin and hypoxia to increase grafted stem cell survival, proliferation, migration to ischemic peri-focal area and ultimately improve neurobehavioral outcomes. We explored the underlying therapeutic efficacy of preconditioning stem cells as well as possible mechanisms and potential risks. Finally, we discussed the prospects of the application of cell-based therapy in clinical patients with ischemic stroke.
Export Options
About this article
Cite this article as:
Cai Hongxia, Zhang Zhijun and Yang Guo-Yuan, Preconditioned Stem Cells: A Promising Strategy for Cell-Based Ischemic Stroke Therapy, Current Drug Targets 2014; 15 (8) . https://dx.doi.org/10.2174/1389450115666140623120010
DOI https://dx.doi.org/10.2174/1389450115666140623120010 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Tear Film Osmolarity, Ocular Surface Disease and Glaucoma: A Review
Current Medicinal Chemistry Selenium: A Cure for Autoimmune Thyroiditis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Molecular Basis of Th2 Development
Current Immunology Reviews (Discontinued) Effects of Olive Oil on TNF-α and IL-6 in Humans: Implication in Obesity and Frailty
Endocrine, Metabolic & Immune Disorders - Drug Targets Effect of Inhibition of Intestinal Cholesterol Absorption on the Prevention of Cholesterol Gallstone Formation
Medicinal Chemistry Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design DNA Repair Proteins as Molecular Therapeutics for Oxidative and Alkylating Lung Injury
Current Gene Therapy Effects of Secondhand Smoke on Thyroid Function
Inflammation & Allergy - Drug Targets (Discontinued) Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs as Cyclooxygenase Inhibitors: State of the Art, Barriers and Perspectives
Current Computer-Aided Drug Design ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets Synthesis and Evaluation of Glycyrrhetic Acid-aromatic Hybrids as Anti-inflammatory Agents
Medicinal Chemistry Brain Protection and Cognitive Function: Cocoa Flavonoids as Nutraceuticals
Current Pharmaceutical Design A Lipid Anchor Improves the Protective Effect of Ectoine in Inflammation
Current Medicinal Chemistry Serotonin as a Modulator of Immune Function: An Overview
Current Immunology Reviews (Discontinued) Improving Cognitive Outcome in Cerebral Malaria: Insights from Clinical and Experimental Research
Central Nervous System Agents in Medicinal Chemistry Protein-Tyrosine Phosphatase 1B as a Potential Drug Target for Obesity
Current Drug Targets - Immune, Endocrine & Metabolic Disorders “Self-Antigenic Universe” and Tuberculosis Vaccine Development
Current Pharmacogenomics and Personalized Medicine The Effects of Current Therapies on Airway Remodeling in Asthma and New Possibilities for Treatment and Prevention
Current Molecular Pharmacology Impact of Polypharmacy on Adherence to Evidence-Based Medication in Patients who Underwent Percutaneous Coronary Intervention
Current Vascular Pharmacology